#United States #San Diego #Class Action #Securities Fraud #Hims & Hers

Hims & Hers Investors Alert

Investors of Hims & Hers Health, Inc. (NYSE: HIMS) have been given an opportunity to take a leading role in a class action lawsuit due to significant financial losses incurred during a specific time frame. According to Robbins Geller Rudman & Dowd LLP, the law firm involved in the case, individuals who purchased shares between April 29, 2025, and June 23, 2025, can apply for the position of lead plaintiff.

The lawsuit, noted as Sookdeo v. Hims & Hers Health, Inc., addresses serious allegations against the company and certain top executives, claiming they violated the Securities Exchange Act of 1934. Notably, another complaint titled Yaghsizian v. Hims & Hers Health, Inc. has been filed regarding these claims.

Background of the Allegations

Hims & Hers is known for its telehealth services, which include prescription medications and personal care products. On April 29, 2025, it was reported that the company had entered into a long-term partnership with Novo Nordisk A/S to sell FDA-approved Wegovy® on its platform. However, the lawsuit alleges that during the class period, the company misled investors regarding its business practices, particularly concerning the promotion of potentially dangerous knockoff versions of Wegovy®, which jeopardized patient safety.

The situation escalated when, on June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, citing concerns over deceptive practices related to the promotion and sale of these illegitimate products. Following this announcement, Hims & Hers stocks plummeted by over 34%, to the detriment of numerous investors.

The Class Action Process

Under the Private Securities Litigation Reform Act of 1995, any investor who suffered losses during the stated period may seek to become the lead plaintiff in this class action lawsuit. The lead plaintiff acts on behalf of all affected investors, guiding the lawsuit forward and making critical decisions about the representation. It’s important to note that one does not need to be a lead plaintiff to receive any potential benefits from the lawsuit.

If you believe you are eligible and wish to take part, you can find more information by reaching out to Robbins Geller through their official website or contacting attorneys J.C. Sanchez and Jennifer N. Caringal directly.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP is a prominent law firm specialized in securities fraud and shareholder litigation. The firm has achieved notable recognition for returning substantial monetary relief for investors involved in securities-related class actions. They were ranked #1 by ISS Securities Class Action Services in securing investor recoveries in four of the last five years, amassing over $2.5 billion for investors in 2024 alone. The firm's reputation is bolstered by its experienced team of 200 attorneys distributed across ten offices globally.

As a potential investor or affected party, it is crucial to stay informed about the developments of this case and to consider taking action if you were impacted by the missteps of Hims & Hers Health, Inc. This situation exemplifies the importance of transparency and accountability in corporate practices.